List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2018259/publications.pdf Version: 2024-02-01



ANCELA CHOU

#	Article	IF	CITATIONS
1	Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Gastroenterology, 2022, 162, 320-324.e4.	0.6	26
2	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104.	0.8	57
3	A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4. JCI Insight, 2022, 7,	2.3	5
	Switch/sucroseâ€nonâ€fermentable (<scp>SWI</scp> / <scp>SNF</scp>) complex (<scp>SMARCA4</scp> ,) Tj	ETQq0 0 0	rgBT /Overloo
4	strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas. Histopathology, 2022, 80, 906-921.	1.6	9
5	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. Modern Pathology, 2022, 35, 836-849.	2.9	20
6	A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS). American Journal of Surgical Pathology, 2022, 46, 774-785.	2.1	5
7	Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems. Pathology, 2022, 54, 855-862.	0.3	3
8	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	0.6	90
9	The 2019 World Health Organization Classification of appendiceal, colorectal and anal canal tumours: an update and critical assessment. Pathology, 2021, 53, 454-461.	0.3	55
10	DNA damageâ€inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression. Histopathology, 2021, 79, 106-116.	1.6	8
11	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Cancer Research, 2021, 81, 3461-3479.	0.4	62
12	Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence features. Scientific Reports, 2021, 11, 10655.	1.6	6
13	Predicting survival in colorectal carcinoma after curative resection: a new prognostic nomogram. Pathology, 2021, , .	0.3	2
14	Kidney transplant cortical necrosis observed during pelvic radiation therapy. Practical Radiation Oncology, 2021, , .	1.1	1
15	A single-cell tumor immune atlas for precision oncology. Genome Research, 2021, 31, 1913-1926.	2.4	87
16	Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Science Advances, 2021, 7, eabh0363.	4.7	23
17	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. American Journal of Surgical Pathology, 2021, 45, 394-404.	2.1	15
18	Sheep in wolf's clothing: squamoid cysts of the pancreatic ducts. ANZ Journal of Surgery, 2021, , .	0.3	0

#	Article	IF	CITATIONS
19	RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas. Modern Pathology, 2020, 33, 657-664.	2.9	22
20	MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Oncogene, 2020, 39, 1821-1829.	2.6	17
21	Unique and distinctive histological features of immunotherapy-related thyroiditis. Pathology, 2020, 52, 271-273.	0.3	4
22	NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases. Modern Pathology, 2020, 33, 924-932.	2.9	51
23	Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma. American Journal of Surgical Pathology, 2020, 44, 536-544.	2.1	61
24	Precision Oncology in Surgery. Annals of Surgery, 2020, 272, 366-376.	2.1	48
25	Molecular Markers Guiding Thyroid Cancer Management. Cancers, 2020, 12, 2164.	1.7	34
26	A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67) Tj ETQq0 0 (1419-1428.) rgBT /Ov 2.1	verlock 10 Tf 5 46
27	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Modern Pathology, 2020, 33, 1811-1821.	2.9	19
28	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	2.9	78
29	Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812092262.	0.6	6
30	When used together SS18–SSX fusionâ€specific and SSX Câ€ŧerminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases. Histopathology, 2020, 77, 588-600.	1.6	50
31	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. Pathology, 2020, 52, 515-521.	0.3	5
32	Decoding a mysterious morphology with molecular pathology: chondroid metaplasia in a metastatic gastrointestinal stromal tumour after imatinib therapy. Pathology, 2020, 52, 396-398.	0.3	2
33	Routine NTRK immunohistochemistry is not a useful screening strategy in unselected pancreatic carcinomas. Pathology, 2020, 52, 398-400.	0.3	0
34	Stromal tumourâ€infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma. Histopathology, 2020, 76, 1095-1101.	1.6	6
35	Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. American Journal of Surgical Pathology, 2019, 43, 35-46.	2.1	74
36	BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma. Pathology, 2018, 50, 345-348.	0.3	8

#	Article	IF	CITATIONS
37	Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut, 2018, 67, 2142-2155.	6.1	100
38	The epithelioid BAP1â€negative and p16â€positive phenotype predicts prolonged survival in pleural mesothelioma. Histopathology, 2018, 72, 509-515.	1.6	17
39	Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma. Endocrine Pathology, 2018, 29, 169-175.	5.2	26
40	ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Human Pathology, 2018, 82, 249-257.	1.1	42
41	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	13.7	716
42	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 2017, 9, .	5.8	208
43	Do significant TFE3 gene rearrangements occur in succinate dehydrogenase-deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution. Modern Pathology, 2017, 30, 1507-1508.	2.9	6
44	Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized. American Journal of Surgical Pathology, 2017, 41, 1433-1442.	2.1	56
45	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.6	174
46	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	1.4	26
47	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	13.7	2,700
48	Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Reviews in Molecular Medicine, 2015, 17, e17.	1.6	51
49	A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2015, 39, 652-659.	2.1	85
50	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	13.7	2,132
51	Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical Cancer Research, 2015, 21, 2029-2037.	3.2	209
52	ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 134-138.	0.6	27
53	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	0.8	67
54	Immunohistochemistry for Myc Predicts Survival in Colorectal Cancer. PLoS ONE, 2014, 9, e87456.	1.1	38

#	Article	IF	CITATIONS
55	BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern Pathology, 2014, 27, 644-650.	2.9	53
56	EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 2014, 46, 501-508.	0.3	9
57	Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas. American Journal of Surgical Pathology, 2014, 38, 560-566.	2.1	71
58	Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma. American Journal of Surgical Pathology, 2014, 38, 1588-1602.	2.1	282
59	Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 2014, 46, 383-388.	0.3	32
60	Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2014, 20, 3187-3197.	3.2	32
61	Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Pathology, 2014, 46, 188-192.	0.3	36
62	Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Human Pathology, 2014, 45, 1697-1703.	1.1	61
63	Personalising pancreas cancer treatment: When tissue is the issue. World Journal of Gastroenterology, 2014, 20, 7849.	1.4	22
64	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Medicine, 2013, 5, 78.	3.6	97
65	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 2013, 31, 1348-1356.	0.8	142
66	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. American Journal of Surgical Pathology, 2013, 37, 1592-1602.	2.1	125
67	Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression. Modern Pathology, 2012, 25, 1307-1313.	2.9	46
68	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	13.7	1,741
69	Renal Tumors Associated With Germline SDHB Mutation Show Distinctive Morphology. American Journal of Surgical Pathology, 2011, 35, 1578-1585.	2.1	184
70	"Pediatric-Type―Gastrointestinal Stromal Tumors Are SDHB Negative ("Type 2â€) GISTs. American Journal of Surgical Pathology, 2011, 35, 1245-1247.	2.1	46
71	BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery, 2010, 148, 1139-1146.	1.0	84
72	Immunohistochemistry for SDHB Divides Gastrointestinal Stromal Tumors (GISTs) into 2 Distinct Types. American Journal of Surgical Pathology, 2010, 34, 636-644.	2.1	210

#	Article	IF	CITATIONS
73	Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Human Pathology, 2010, 41, 805-814.	1.1	235